NCT05839236

COVID-19 Vaccination Detoxification in LDL-C

COVID-19 Vaccination Detoxication in Low Density Lipoprotein Cholesterol

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Yang I. Pachankis · Individual
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The study hypothesizes that SARS-CoV-2 vaccination poisoning hibernates in human host in Low Density Lipoprotein Cholesterol (LDL-C). The clinical trial is a follow-up from the intervention trial with NCT number NCT05711810. It tests the use of Atorvastatin Calcium Tablets for detoxification and prevention of blood acidification, and the use of the Chinese herb compounded Anti-Viral Granules for the detoxification in the endocrine system.

Conditions

• COVID-19 Stress Syndrome
• COVID-19 Vaccine Adverse Reaction
• COVID-19-Associated Thromboembolism
• COVID-19 Post-Intensive Care Syndrome
• COVID-19-Associated Stroke
• COVID-19 Respiratory Infection

Interventions

Type	Name	Description
COMBINATION_PRODUCT	Atorvastatin Calcium Tablets	The intervention observes the effects of the medicines on the participant's health without the continued interventions on blood pressure. Rescue medicines will be used once if the blood pressure rise again beyond the healthy range.

Timeline

• Start date: 2023-05-01
• Primary completion: 2023-06-30
• Completion: 2023-07-31
• First posted: 2023-05-03
• Last updated: 2023-05-06

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study